<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015170</url>
  </required_header>
  <id_info>
    <org_study_id>005/2008</org_study_id>
    <nct_id>NCT01015170</nct_id>
  </id_info>
  <brief_title>STOP Study: Effectiveness of Zyban in a Clinical Population</brief_title>
  <official_title>The STOP Study: Real World Effectiveness of Zyban Treatment in a Clinical Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario Ministry of Health and Long Term Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the significant health, social and economic costs of cigarette smoking, 17% of
      Ontarians still currently smoke. Use of smoking cessation pharmacotherapy such as Zyban
      (bupropion HCl) has been shown to double quit rates but such medications are under-utilized
      by smokers attempting to quit. It has been suggested that the high price of pharmacotherapy
      may act as a barrier to accessing such treatment.The main objective of this study is to
      evaluate the methods and effectiveness of providing smokers who want to quit with 8 weeks of
      free Zyban in combination with smoking cessation counselling through family health teams and
      community health centres across the province.

      Hypothesis: Ontario smokers who receive 8-weeks of free bupropion in combination with brief
      counselling will have higher smoking cessation rates than the standard population cessation
      rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nicotine dependence, like other addictive disorders, can be characterized as a chronic,
      relapsing disease (Leshner, 1997). Although there is significant morbidity and mortality
      associated with this disorder, the majority of smokers are not treated adequately to the
      widely accepted goal of complete long-term abstinence from smoking. This may be due to the
      under-utilization of accepted pharmacotherapies for the treatment of tobacco dependence.

      Bupropion (Zyban) Bupropion is the first line of non-nicotine-based pharmacotherapy for
      smoking cessation. Several large-scale clinical trials have shown bupropion to be an
      efficacious smoking cessation aid (Hurt et al., 1997; Jorenby et al., 1999; Ahluwalia et al.,
      2002). In one such study, a 44% abstinence rate was reported for seven weeks of treatment
      with bupropion at 300 mg/day, compared to 19% for placebo (Hurt et al, 1997). A recent
      meta-analysis has reported that bupropion monotherapy approximately doubles the rate of
      smoking cessation (OR 1.94) (Hughes et al, 2007).

      Despite its efficacy, bupropion's mechanism of action is unclear. Attenuation of
      abstinence-associated increase in craving and withdrawal symptoms has been suggested as
      possible mechanisms of bupropion's effect on smoking behaviour in a few randomized clinical
      trials (Jorneby et al., 1999; Shiffman et al., 2000; Lerman et al., 2002; Durcan et al,
      2002). However, these effects are not universally demonstrated (Hurt et al., 1997; Shiffman
      et al., 2000). Other possible bio-behavioral mechanisms have remained largely unexplored.
      Using positron emission tomography (PET) it has been shown that in contrast to untreated
      smokers, when bupropion-treated smokers were exposed to cigarette-related cues there was less
      metabolic activation in their anterior cingulate cortex, a region of the brain previously
      shown to be activated by cigarette cues (Brody et al., 2004;Brody et al., 2002).

      STOP Study Background and Rationale

      Treatment with pharmacotherapy such as nicotine replacement therapy (NRT) or Zyban is a safe
      and effective smoking cessation strategy that can double the chance of quitting successfully
      over the long-term (Cornuz, 2007). However, research has shown that most smokers who are
      interested in quitting do not use pharmacotherapy to aid in their quit attempt.
      Misconceptions about the harmful effects of nicotine are a strong barrier to the use of
      pharmacotherapy. The cost of pharmacotherapy may also be a significant contributor to the
      under-utilization of smoking cessation aids such as NRT and Zyban. Karnath (2001) suggested
      that the high cost of successful pharmacotherapy treatment for smoking cessation may be a
      barrier for some individuals. Moreover, Cokkinides et al (2005) reported that smokers with
      private insurance were more likely to use smoking cessation pharmacotherapies than smokers
      without insurance. The addition of free NRT to a group behavioural cessation program
      substantiated these claims by showing an increase in quit rates from 38% to 65% (Alberg et
      al, 2004). These studies suggest that economic barriers may prevent smokers from using
      pharmacotherapy in their attempts to quit smoking.

      The study proposed herein will introduce free bupropion as another treatment option for
      smoking cessation for Ontario smokers. Community Health Centres and Aboriginal Health Access
      Centres are interdisciplinary health models that are able to help individuals who would
      otherwise be prevented from accessing health services due to social and geographic barriers.
      As they aim to eliminate these other barriers and consequently control for them, they are an
      ideal health model for determining whether eliminating the economic barriers of smoking
      cessation improves smoking cessation rates. Family Health Teams are more recent health models
      that provide integrated and interdisciplinary primary health care. Since they are able to
      treat large and diverse populations, they are an ideal health model for accessing Ontario
      smokers.

      Objectives

      1. To evaluate the effectiveness of 8-weeks of free bupropion in combination with brief
      counselling through family health teams, community health centres and aboriginal health
      access centres in Ontario for smoking cessation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-day Point Prevalence of Smoking Abstinence</measure>
    <time_frame>End of Treatment (8 weeks after Zyban start date)</time_frame>
    <description>Number of participants who report &quot;Not Smoking (not even a puff) in past 7 days&quot; when asked at week 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Quit Attempt (at Least 24 Hours of Abstinence)</measure>
    <time_frame>End of Treatment (8 weeks after Zyban start date)</time_frame>
    <description>Number of participants who report a serious quit attempt at End of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day Point Prevalence of Smoking Abstinence</measure>
    <time_frame>6 months after Zyban start date</time_frame>
    <description>Number of participants who report &quot;Not Smoking (not even a puff) in past 7 days&quot; when asked 6 months after Zyban start date</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">454</enrollment>
  <condition>Cigarette Smoking</condition>
  <condition>Nicotine Addiction</condition>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Bupropion HCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 8 week of bupropion SR (150mg BID) + counseling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion HCl</intervention_name>
    <description>150mg BID for up to 8 weeks + counseling</description>
    <arm_group_label>Bupropion HCl</arm_group_label>
    <other_name>Zyban</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ontario resident

          -  18 years of age or older

          -  Current daily cigarette smoker who smokes 10 or more cigarettes per day and has smoked
             &gt; 100 cigarettes in their lifetime

          -  Want to quit smoking cigarettes within 30 days of assessment

          -  Willingness and capacity to give written informed consent and to comply with study
             protocol

        Exclusion Criteria:

          -  Enrollment in any of the STOP Study NRT models in the past 6 months

          -  Currently receiving Wellbutrin SR or any medication containing bupropion hydrochloride

          -  Current seizure disorder or history of seizures

          -  Current or prior diagnosis of bulimia or anorexia nervosa

          -  Current diagnosis of bipolar disorder

          -  History of head trauma

          -  Allergy or sensitivity to Zyban, Wellbutrin or bupropion

          -  Undergoing abrupt withdrawal from alcohol, benzodiazepines or other sedatives

          -  Currently taking monoamine oxidase (MAO) inhibitors, or thioridazine

          -  Pregnant or breastfeeding or at risk of becoming pregnant

          -  Central nervous system (CNS) tumor

          -  Severe hepatic impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Selby, MD, MHSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Youth Centre</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cottage Country Family Health Team</name>
      <address>
        <city>Bracebridge</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bramalea Community Health Centre</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Downtown Nurse Practitioner Clinic</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beausoleil Family Health Centre</name>
      <address>
        <city>Christian Island</city>
        <state>Ontario</state>
        <zip>L9M0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgian Bay Family Health Team</name>
      <address>
        <city>Collingwood</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Renfrew Family Health Team</name>
      <address>
        <city>Deep River</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elliot Lake Family Health Team</name>
      <address>
        <city>Elliot Lake</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Englehart &amp; District Family Health Team</name>
      <address>
        <city>Englehart</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stonegate Community Health Centre</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haliburton Highlands Family Health Team</name>
      <address>
        <city>Haliburton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algonquin Family Health Team</name>
      <address>
        <city>Huntsville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Beglund Community Health Centre</name>
      <address>
        <city>Ignace</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorWest Community Health Centre</name>
      <address>
        <city>Longlac</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summerville Family Health Team</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Forest Family Health Team</name>
      <address>
        <city>Mount Forest</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dufferin Area Family Health Team</name>
      <address>
        <city>Orangeville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset West Community Health Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PrimaCare Community Family Health Team</name>
      <address>
        <city>Paris</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Durham Family Health Team</name>
      <address>
        <city>Pickering</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Edward Family Health Team</name>
      <address>
        <city>Picton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stratford Family Health Team</name>
      <address>
        <city>Stratford</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorWest Community Health Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandwich Community Health Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.stopstudy.ca</url>
    <description>Click here for more information about the study: STOP Study: Effectiveness of Zyban in a Clinical Population</description>
  </link>
  <link>
    <url>http://www.camh.net/research</url>
    <description>Information about research at the Centre for Addiction and Mental Health, Canada's largest mental health and addiction teaching hospital, fully affiliated with the University of Toronto, and a PAHO/WHO Collaborating Centre.</description>
  </link>
  <reference>
    <citation>Alberg AJ, Stashefsky Margalit R, Burke A, Rasch KA, Stewart N, Kline JA, Ernst PA, Avey A, Hoffman SC. The influence of offering free transdermal nicotine patches on quit rates in a local health department's smoking cessation program. Addict Behav. 2004 Dec;29(9):1763-78.</citation>
    <PMID>15530720</PMID>
  </reference>
  <reference>
    <citation>Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA. 2002 Jul 24-31;288(4):468-74.</citation>
    <PMID>12132977</PMID>
  </reference>
  <reference>
    <citation>Brody AL, Mandelkern MA, London ED, Childress AR, Lee GS, Bota RG, Ho ML, Saxena S, Baxter LR Jr, Madsen D, Jarvik ME. Brain metabolic changes during cigarette craving. Arch Gen Psychiatry. 2002 Dec;59(12):1162-72.</citation>
    <PMID>12470133</PMID>
  </reference>
  <reference>
    <citation>Brody AL, Mandelkern MA, Lee G, Smith E, Sadeghi M, Saxena S, Jarvik ME, London ED. Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study. Psychiatry Res. 2004 Apr 30;130(3):269-81. Erratum in: Psychiatry Res. 2004 Dec 15;132(2):183-4.</citation>
    <PMID>15135160</PMID>
  </reference>
  <reference>
    <citation>Cokkinides VE, Ward E, Jemal A, Thun MJ. Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. Am J Prev Med. 2005 Jan;28(1):119-22.</citation>
    <PMID>15626567</PMID>
  </reference>
  <reference>
    <citation>Durcan MJ, Deener G, White J, Johnston JA, Gonzales D, Niaura R, Rigotti N, Sachs DP. The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clin Ther. 2002 Apr;24(4):540-51.</citation>
    <PMID>12017399</PMID>
  </reference>
  <reference>
    <citation>Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2000;(4):CD000031. Review. Update in: Cochrane Database Syst Rev. 2002;(1):CD000031.</citation>
    <PMID>11034670</PMID>
  </reference>
  <reference>
    <citation>Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997 Oct 23;337(17):1195-202.</citation>
    <PMID>9337378</PMID>
  </reference>
  <reference>
    <citation>Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999 Mar 4;340(9):685-91.</citation>
    <PMID>10053177</PMID>
  </reference>
  <reference>
    <citation>Leshner AI. Addiction is a brain disease, and it matters. Science. 1997 Oct 3;278(5335):45-7.</citation>
    <PMID>9311924</PMID>
  </reference>
  <reference>
    <citation>Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, Niaura R, Epstein L. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 2002 Jul 1;67(2):219-23.</citation>
    <PMID>12095672</PMID>
  </reference>
  <reference>
    <citation>Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Gnys M, Evoniuk G, DeVeaugh-Geiss J. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl). 2000 Jan;148(1):33-40.</citation>
    <PMID>10663415</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <results_first_submitted>June 29, 2016</results_first_submitted>
  <results_first_submitted_qc>February 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2017</results_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Dr. Peter Selby</investigator_full_name>
    <investigator_title>Clinician Scientist, Addictions Program</investigator_title>
  </responsible_party>
  <keyword>smoking cessation</keyword>
  <keyword>nicotine addiction</keyword>
  <keyword>Zyban</keyword>
  <keyword>bupropion hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share data</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupropion HCl</title>
          <description>Up to 8 week of bupropion SR (150mg BID) + counseling.
bupropion HCl: 150mg BID for up to 8 weeks + counseling</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="454"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="239"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Ontario smokers who are interested in quitting smoking.</population>
      <group_list>
        <group group_id="B1">
          <title>Buproprion &amp; Behavioural Support</title>
          <description>8 weeks of buproprion-SR + brief counselling for smoking cessation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="454"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="415"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.5" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education level attained</title>
          <description>highest level of education attained</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>up to highschool</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post secondary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Employed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not employed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Income category</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>up to $40,000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>more than $40,000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes per day (cpd)</title>
          <description># cigarettes smoked per day</description>
          <units># cigarettes smoked per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.5" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age first smoked</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.1" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age smoked daily</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.4" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time to first morning cigarette</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>15 minutes or less</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>more than 15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title># quit attempts in the past</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 - 2 quit attempts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 or more quit attempts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Importance of quitting smoking</title>
          <description>scale of importance of quitting (1 to 10)
1 - least important 10- most important</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Confidence in quitting smoking</title>
          <description>Confidence in quitting smoking
1- very little confidence 10- very confident</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ever had a psychiatric diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>7-day Point Prevalence of Smoking Abstinence</title>
        <description>Number of participants who report &quot;Not Smoking (not even a puff) in past 7 days&quot; when asked at week 8</description>
        <time_frame>End of Treatment (8 weeks after Zyban start date)</time_frame>
        <population>Participants who completed survey 8 weeks after Zyban start date</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Replacement &amp; Behavioural Support</title>
            <description>Nicotine Replacement Therapy: Transdermal nicotine patch, nicotine gum, nicotine inhaler, nicotine lozenge
&amp; Smoking cessation counselling-relapse prevention strategies.</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Point Prevalence of Smoking Abstinence</title>
          <description>Number of participants who report &quot;Not Smoking (not even a puff) in past 7 days&quot; when asked at week 8</description>
          <population>Participants who completed survey 8 weeks after Zyban start date</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Still smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quit smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Quit Attempt (at Least 24 Hours of Abstinence)</title>
        <description>Number of participants who report a serious quit attempt at End of treatment</description>
        <time_frame>End of Treatment (8 weeks after Zyban start date)</time_frame>
        <population>This secondary outcome was not collected at 8 week followup.</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion HCl and Counselling</title>
            <description>Bupropion HCl Up to 8 week of bupropion SR (150mg BID) + counseling.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Quit Attempt (at Least 24 Hours of Abstinence)</title>
          <description>Number of participants who report a serious quit attempt at End of treatment</description>
          <population>This secondary outcome was not collected at 8 week followup.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7-day Point Prevalence of Smoking Abstinence</title>
        <description>Number of participants who report &quot;Not Smoking (not even a puff) in past 7 days&quot; when asked 6 months after Zyban start date</description>
        <time_frame>6 months after Zyban start date</time_frame>
        <population>Number of participants who completed 6 month post treatment survey</population>
        <group_list>
          <group group_id="O1">
            <title>Buproprion &amp; Behavioural Support</title>
            <description>8 weeks of buproprion-SR + brief counselling for smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Point Prevalence of Smoking Abstinence</title>
          <description>Number of participants who report &quot;Not Smoking (not even a puff) in past 7 days&quot; when asked 6 months after Zyban start date</description>
          <population>Number of participants who completed 6 month post treatment survey</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Smoked in past 7 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="320"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did not smoke in past 7 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bupropion HCl</title>
          <description>Up to 8 week of bupropion SR (150mg BID) + counseling.
bupropion HCl: 150mg BID for up to 8 weeks + counseling</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>ER visit for Chest pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>ER visit for Pancreatitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>head injury</sub_title>
                <description>Participant fell and hospitalized for head injury</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousess</sub_title>
                <description>Loss of consciousness</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Health issues</sub_title>
                <description>ER visit for mental health issues</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>wheezing</sub_title>
                <description>ER visit for wheezing</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Peter Selby; Dr. Laurie Zawertailo Principal Investigator</name_or_title>
      <organization>Centre for Addiction and Mental Health</organization>
      <phone>416-535-8501 ext 77422</phone>
      <email>laurie.zawertailo@camh.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

